{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:09:20Z","timestamp":1761919760488,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.clinre.2013.08.003","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T15:15:43Z","timestamp":1385046943000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predictors of the therapeutic response in hepatitis C. A 2013 update"],"prefix":"10.1016","volume":"38","author":[{"given":"Cl\u00e9mence","family":"Arnaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Tr\u00e9po","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2013.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0010","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"55","author":"Anon.","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0020","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.2174\/138161208784746851","article-title":"Therapy of acute hepatitis C: a review of literature","volume":"14","author":"Santantonio","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinre.2013.08.003_bib0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1574-6976.2011.00319.x","article-title":"Failure of innate and adaptive immune responses in controlling hepatitis C virus infection","volume":"36","author":"Thimme","year":"2012","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.clinre.2013.08.003_bib0030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2013.08.003_bib0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)\/ribavirin","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/gut.2005.074062","article-title":"Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C","volume":"55","author":"Diago","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2013.08.003_bib0045","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/hep.21407","article-title":"IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection","volume":"44","author":"Lagging","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0050","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/507307","article-title":"Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection","volume":"194","author":"Romero","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinre.2013.08.003_bib0055","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/QAI.0b013e3180559219","article-title":"Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus\/HIV-coinfected patients","volume":"45","author":"Zeremski","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clinre.2013.08.003_bib0060","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/hep.22500","article-title":"Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C","volume":"48","author":"Zeremski","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0065","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1086\/646614","article-title":"Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection","volume":"200","author":"Zeremski","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinre.2013.08.003_bib0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2013.08.003_bib0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2013.08.003_bib0085","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinre.2013.08.003_bib0090","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinre.2013.08.003_bib0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0100","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/hep.25582","article-title":"Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection","volume":"55","author":"Fischer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2893.2012.01645.x","article-title":"HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism","volume":"20","author":"Stenkvist","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.clinre.2013.08.003_bib0110","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2012.04.036","article-title":"Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C","volume":"57","author":"Stattermayer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2011.09.008","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C","volume":"56","author":"Asselah","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0120","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/hep.25647","article-title":"Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response","volume":"56","author":"Naggie","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2011.10.004","article-title":"Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1","volume":"56","author":"Howell","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2011.01.050","article-title":"IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C","volume":"55","author":"Bochud","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0135","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23862","article-title":"Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus","volume":"52","author":"Ndongo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2005.03.023","article-title":"Enveloped particles in the serum of chronic hepatitis C patients","volume":"336","author":"Petit","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0145","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/jmv.21562","article-title":"Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody","volume":"81","author":"Ndongo","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/hep.24386","article-title":"Long-term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes","volume":"54","author":"Ndongo-Thiam","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0155","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinre.2013.08.003_bib0160","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.26443","article-title":"Interferon-lambda polymorphisms and hepatitis C virus clearance revisited","volume":"58","author":"Lupberger","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0165","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.20130012","article-title":"IL28B expression depends on a novel TT\/-G polymorphism which improves HCV clearance prediction","volume":"210","author":"Bibert","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinre.2013.08.003_bib0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/hep.24056","article-title":"Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response","volume":"53","author":"Darling","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0175","doi-asserted-by":"crossref","first-page":"e17232","DOI":"10.1371\/journal.pone.0017232","article-title":"Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms","volume":"6","author":"Lagging","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinre.2013.08.003_bib0180","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.23850","article-title":"Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection","volume":"52","author":"Grebely","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.gastro.2011.09.039","article-title":"Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection","volume":"142","author":"Beinhardt","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0190","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrgastro.2011.49","article-title":"A new standard of care for the treatment of chronic HCV infection","volume":"8","author":"Hofmann","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0195","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2012.09.023","article-title":"Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?","volume":"58","author":"Pascale","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0200","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0205","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(12)61106-4","article-title":"100% SVR in IL28B SNP rs12979860C\/C patients treated with 12weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial","volume":"56","author":"Bronowicki","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0210","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1053\/j.gastro.2012.01.046","article-title":"Genetic factors and hepatitis C virus infection","volume":"142","author":"Thompson","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2013.08.003_bib0215","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.dld.2012.09.011","article-title":"Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents era","volume":"45","author":"Bruno","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinre.2013.08.003_bib0220","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) \u2013 NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2013.08.003_bib0225","first-page":"243","article-title":"Hepatitis C virus therapy update 2013","volume":"29","author":"Casey","year":"2013","journal-title":"Curr Opin Gastroenterol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:19:55Z","timestamp":1761895195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740113001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S2210740113001770"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2013.08.003","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of the therapeutic response in hepatitis C. A 2013 update","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2013.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}